Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

latent tuberculosis infection (LTBI) - Clinical Profile, Treatments & Trials | Kisho | Kisho

Rare Disease

latent tuberculosis infection

MONDO:0040753

Also known as:LTBIinactive TBinactive tuberculosis

Find Clinical TrialsTrials

Overview

Mycobacterium tuberculosis infection that does not induce infectious expression of the disease in the affected person, although it can cause continuous immune response generated towards TB antigens; person having LTBI are asymptomatic and acting as a reservoir of active tuberculosis tuberculosis cases and Mycobacterium tuberculosis and run a 5-10% risk of reactivating tuberculosis throughout their lives.

Treatments1 FDA approved

Clinical Trials53 registered · 20 recruiting

Diagnosis

Biomarker and diagnostic research for latent tuberculosis infection has been reported in the published literature.

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

1 FDA-approved treatment is available for latent tuberculosis infection, including RIFAPENTINE (PRIFTIN, approved 1998).

Approved Therapies

Brand Name	Generic Name	Mechanism	Approved	Market Status

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

53 clinical trials registered, 20 recruiting. Interventions under study include other interventions, drug therapy, biologic therapy, and medical devices. Pipeline includes 4 PHASE4, 4 PHASE3, 3 PHASE2. Research is sponsored by a mix of industry and academic institutions.

NCT ID	Title	Phase	Sponsor	Status
[NCT03474029](https://clinicaltrials.gov/study/NCT03474029)

Data assembled from 4 of 12 sources · Last updated Sep 18, 2026, 6:36 PM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

Questions for Your Care Team

→What are the benefits and potential side effects of PRIFTIN for managing latent tuberculosis infection?
→Are any of the 53 active clinical trials a good fit for my situation?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

Research Type	Count	% of Total
Disease patterns and progression	45	31%
Research summaries	41	28%
Testing and diagnosis research	30	21%
Clinical study results	12	8%
Laboratory research	11	8%
Other research	5	3%
Patient case studies	1	1%
New treatment approaches	1	1%

latent tuberculosis infection

Overview

Diagnosis

Treatment

Approved Therapies

Research Landscape

Medical References

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Clinical Trials

Recent Publications